JP2010533737A - キメラ水痘帯状疱疹ウイルス−ウイルス様粒子 - Google Patents

キメラ水痘帯状疱疹ウイルス−ウイルス様粒子 Download PDF

Info

Publication number
JP2010533737A
JP2010533737A JP2010517201A JP2010517201A JP2010533737A JP 2010533737 A JP2010533737 A JP 2010533737A JP 2010517201 A JP2010517201 A JP 2010517201A JP 2010517201 A JP2010517201 A JP 2010517201A JP 2010533737 A JP2010533737 A JP 2010533737A
Authority
JP
Japan
Prior art keywords
protein
chimeric
vzv
vlp
chimeric vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010517201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533737A5 (OSRAM
Inventor
スミス，ゲイル
プシュコ，ピーター
Original Assignee
ノババックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノババックス，インコーポレイテッド filed Critical ノババックス，インコーポレイテッド
Publication of JP2010533737A publication Critical patent/JP2010533737A/ja
Publication of JP2010533737A5 publication Critical patent/JP2010533737A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/609—Vectors comprising as targeting moiety peptide derived from defined protein from viruses positive strand RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2010517201A 2007-07-19 2008-07-21 キメラ水痘帯状疱疹ウイルス−ウイルス様粒子 Withdrawn JP2010533737A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95070707P 2007-07-19 2007-07-19
US97059207P 2007-09-07 2007-09-07
US7183508P 2008-05-20 2008-05-20
PCT/US2008/070636 WO2009012487A2 (en) 2007-07-19 2008-07-21 Chimeric varicella zoster virus-virus like particles

Publications (2)

Publication Number Publication Date
JP2010533737A true JP2010533737A (ja) 2010-10-28
JP2010533737A5 JP2010533737A5 (OSRAM) 2011-08-11

Family

ID=40260107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010517201A Withdrawn JP2010533737A (ja) 2007-07-19 2008-07-21 キメラ水痘帯状疱疹ウイルス−ウイルス様粒子

Country Status (14)

Country Link
US (1) US20110008838A1 (OSRAM)
EP (3) EP2176427A4 (OSRAM)
JP (1) JP2010533737A (OSRAM)
CN (1) CN101801411A (OSRAM)
CA (1) CA2693899A1 (OSRAM)
CY (1) CY1116583T1 (OSRAM)
DK (1) DK2540312T3 (OSRAM)
ES (1) ES2542644T3 (OSRAM)
HR (1) HRP20150758T1 (OSRAM)
HU (1) HUE025702T2 (OSRAM)
PL (1) PL2540312T3 (OSRAM)
PT (1) PT2540312E (OSRAM)
SI (1) SI2540312T1 (OSRAM)
WO (2) WO2009012487A2 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2370099T3 (en) 2008-12-09 2016-08-01 Novavax Inc Rsv f modified proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
SG175781A1 (en) 2009-05-01 2011-12-29 Redbiotec Ag Recombinant virus-like particles encoded by multi-gene vector
PL222497B1 (pl) 2009-06-26 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
EP2448596B1 (en) 2009-07-02 2016-01-06 Massachusetts Institute of Technology Compositions and methods for diagnosing and/or treating influenza infection
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
JP2013541528A (ja) 2010-09-21 2013-11-14 マサチューセッツ インスティテュート オブ テクノロジー ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置
SG189236A1 (en) 2010-10-04 2013-05-31 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
AU2012212264B2 (en) * 2011-01-31 2016-01-28 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
BR112014006694A2 (pt) 2011-09-20 2020-11-17 Mount Sinai School Of Medicine vacinas contra o vírus influenza e usos dessas
AU2013201495B2 (en) * 2011-09-30 2015-12-03 Novavax, Inc. Recombinant nanoparticle RSV F vaccine for respiratory syncytial virus
CN108130345A (zh) * 2012-01-24 2018-06-08 乔治亚大学研究基金公司 基于副流感病毒5的疫苗
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
MX2015010305A (es) * 2013-02-11 2015-11-18 Novavax Inc Vacuna de combinacion para virus sincitial respiratorio e influenza.
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
WO2019023196A1 (en) 2017-07-24 2019-01-31 Novavax, Inc. METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
US11278612B2 (en) 2018-03-19 2022-03-22 Novavax, Inc. Multivalent influenza nanoparticle vaccines
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN110237248A (zh) * 2019-07-01 2019-09-17 大连民族大学 一种带状疱疹疫苗的制备方法
MX2022016502A (es) * 2020-06-17 2023-03-13 Meissa Vaccines Inc Proteinas quimericas de rsv y coronavirus, composiciones inmunogenicas y metodos de uso.
GB202017649D0 (en) * 2020-11-09 2020-12-23 Autolus Ltd Polypeptide
KR102680105B1 (ko) * 2021-05-17 2024-07-02 대한민국 코로나19 바이러스 및 인플루엔자 h1n1 바이러스에 대한 바이러스 유사입자 및 이의 용도
KR20250143785A (ko) * 2023-01-19 2025-10-02 시아먼 유니버시티 수두-대상포진 바이러스의 ge 및 gi 융합 단백질 및 이의 용도
CN116284455B (zh) * 2023-04-17 2024-10-11 北京康乐卫士生物技术股份有限公司 一种带状疱疹病毒疫苗的嵌合抗原及其应用
CN120418435A (zh) * 2023-11-13 2025-08-01 石药集团巨石生物制药有限公司 一种抵抗带状疱疹的mRNA疫苗及其制备方法
CN120020142A (zh) * 2023-11-20 2025-05-20 上海蓝鹊生物医药有限公司 一种vzv抗原变体、核酸、药物组合物及其应用
WO2025180455A1 (en) * 2024-02-27 2025-09-04 Therorna Inc. A circular rna vaccine against herpes zoster virus and the use thereof
CN119684476B (zh) * 2025-02-21 2025-05-06 中国医学科学院医学生物学研究所 一种抗水痘-带状疱疹病毒单克隆抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
AU2003219760A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
MXPA04010902A (es) * 2004-11-03 2006-05-08 Alvaro Raul Lara Rodriguez Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple.
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CN103865892B (zh) * 2005-10-18 2017-04-12 诺瓦瓦克斯股份有限公司 功能性流感病毒样颗粒(vlp)

Also Published As

Publication number Publication date
PT2540312E (pt) 2015-08-31
WO2009012487A2 (en) 2009-01-22
CN101801411A (zh) 2010-08-11
EP2540312A1 (en) 2013-01-02
EP2175883A4 (en) 2011-11-30
EP2175883A2 (en) 2010-04-21
WO2009012489A1 (en) 2009-01-22
DK2540312T3 (en) 2015-07-20
HRP20150758T1 (hr) 2015-08-14
HUE025702T2 (en) 2016-04-28
EP2176427A1 (en) 2010-04-21
PL2540312T3 (pl) 2015-10-30
CA2693899A1 (en) 2009-01-22
WO2009012487A3 (en) 2009-12-30
US20110008838A1 (en) 2011-01-13
SI2540312T1 (sl) 2015-08-31
CY1116583T1 (el) 2017-03-15
ES2542644T3 (es) 2015-08-07
EP2176427A4 (en) 2011-10-05
EP2540312B1 (en) 2015-04-15

Similar Documents

Publication Publication Date Title
US12357684B2 (en) Modified RSV F proteins and methods of their use
JP2010533737A (ja) キメラ水痘帯状疱疹ウイルス−ウイルス様粒子
JP6195965B2 (ja) 狂犬病糖タンパク質ウイルス様粒子（ｖｌｐ）
JP5714799B2 (ja) 機能的インフルエンザウイルス様粒子（ｖｌｐ）
US8551756B2 (en) Avian influenza chimeric VLPS
US20140227309A1 (en) Combination vaccine for respiratory syncytial virus and influenza
KR20100063030A (ko) 바리셀라 조스터 바이러스-바이러스 유사 입자(ＶＬＰｓ) 및 항원
US11446374B2 (en) Modified RSV F proteins and methods of their use
WO2010148386A1 (en) Swine-origin influenza a (h1n1) virus-like particles and methods of use thereof
US20160000902A1 (en) Combination vaccine for respiratory syncytial virus and influenza

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110627

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120510